Merck faces Canadian class action; Takeda eyes Indian pharma, paper says

> Researchers at TauRx Therapeutics are heralding their breakthrough data on a drug to treat Alzheimer's. Report

> A Canadian court has certified another class-action lawsuit against Merck over its former painkiller Vioxx, for which the U.S. drugmaker is doling out billions of dollars to cover American settlements. Report

> Takeda Pharmaceuticals is keenly eyeing India-based Torrent Pharmaceuticals as a possible acquisition, the Times of India reports. Report

> The FDA approved Stavzor as a treatment for manic episodes associated with bipolar disorder, drug maker Noven Pharmaceuticals announced Wednesday. Report

> Sun Pharmaceuticals' proposed takeover of Taro--already facing problems from investors--was dealt another blow as Israeli politicians raised fears that the deal might cost 650 jobs. Report

> Dr. Reddys Laboratories said that the company acquired a stake in Perlecan Pharma from Citigroup Venture Capital International, Mauritius and IDBI Trusteeship Services. Report

> Sciele Pharma, a specialty pharmaceutical company, posted higher profit for the second quarter helped by higher income from discontinued operations and increased revenues. Report

> Canada's Cytochroma has garnered CDN $45 million in a Series C round led by Mitsubishi Tanabe Pharma Corporation. Report

> UCB was dealt a severe setback when the FDA issued a not-approvable letter late Tuesday for lacosamide, an experimental therapy for diabetic neuropathic pain. UCB report

> The angry exchanges between Emergent BioSolutions and Protein Sciences keep getting nastier. Both companies now accuse each other of breaking their $78 million merger pact. Report

And Finally... Hay fever and asthma sufferers, rejoice: You're up to 25 percent less likely to get Non-Hodgkins Lymphoma. Report

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.